H
Ho Jin Kim
Researcher at National Cancer Research Institute
Publications - 204
Citations - 9441
Ho Jin Kim is an academic researcher from National Cancer Research Institute. The author has contributed to research in topics: Neuromyelitis optica & Multiple sclerosis. The author has an hindex of 40, co-authored 201 publications receiving 7054 citations. Previous affiliations of Ho Jin Kim include University College London & Dongseo University.
Papers
More filters
Journal ArticleDOI
Distinct Effector Cytokine Profiles of Memory and Naive Human B Cell Subsets and Implication in Multiple Sclerosis
Martin Duddy,Masaaki Niino,Femina Adatia,Sherry Hebert,Mark S. Freedman,Harry Atkins,Ho Jin Kim,Amit Bar-Or +7 more
TL;DR: This study confirms that effector cytokine production by normal human B cells is context dependent and demonstrates that this involves the reciprocal regulation of proinflammatory and anti-inflammatory cytokines, and proposes a model that ascribes distinct and proactive roles to memory and naive B cell subsets in the regulation of memory immune responses and in autoimmunity.
Journal ArticleDOI
MOG encephalomyelitis: International recommendations on diagnosis and antibody testing
Sven Jarius,Friedemann Paul,Friedemann Paul,Orhan Aktas,Nasrin Asgari,Russell C. Dale,J. de Seze,Diego Franciotta,Kazuo Fujihara,Anu Jacob,Ho Jin Kim,Ingo Kleiter,T. Kümpfel,Michael J. Levy,Jacqueline Palace,Klemens Ruprecht,Albert Saiz,Corinna Trebst,Brian G. Weinshenker,Brigitte Wildemann +19 more
TL;DR: In this article, the authors proposed indications for MOG-IgG testing based on expert consensus, and gave a list of conditions atypical for MG-EM (red flags) that should prompt physicians to challenge a positive MOG IgG test result, and provided recommendations regarding assay methodology, specimen sampling and data interpretation.
Journal ArticleDOI
MRI characteristics of neuromyelitis optica spectrum disorder An international update
Ho Jin Kim,Friedemann Paul,Marco Aurélio Lana-Peixoto,Silvia Tenembaum,Nasrin Asgari,Jacqueline Palace,Eric C. Klawiter,Douglas Kazutoshi Sato,Jérôme De Seze,Jens Wuerfel,Brenda Banwell,Pablo Villoslada,Albert Saiz,Kazuo Fujihara,Su-Hyun Kim +14 more
TL;DR: MRI findings of neuromyelitis optica and its spectrum disorder (NMOSD) are reviewed, finding brain, optic nerve, and spinal cord MRI findings of NMOSD to be of increased interest.
Journal ArticleDOI
Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder
Sean J. Pittock,Achim Berthele,Kazuo Fujihara,Kazuo Fujihara,Ho Jin Kim,Michael J. Levy,Michael J. Levy,Jacqueline Palace,Ichiro Nakashima,Ichiro Nakashima,Murat Terzi,N. A. Totolyan,Shanthi Viswanathan,Kai-Chen Wang,A Pace,Kenji P Fujita,R Armstrong,Dean M. Wingerchuk +17 more
TL;DR: Patients with AQP4-IgG-positive NMOSD who received eculizumab had a significantly lower risk of relapse than those who received placebo, and there was no significant between-group difference in measures of disability progression.
Journal ArticleDOI
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial.
Bruce A.C. Cree,Jeffrey Bennett,Ho Jin Kim,Brian G. Weinshenker,Sean J. Pittock,Dean M. Wingerchuk,Kazuo Fujihara,Friedemann Paul,Gary Cutter,Romain Marignier,Ari J. Green,Orhan Aktas,Hans-Peter Hartung,Fred D. Lublin,Jorn Drappa,Gerard Barron,Soraya Madani,John N. Ratchford,Dewei She,Daniel Cimbora,Eliezer Katz,N-MOmentum study investigators +21 more
TL;DR: Compared with placebo, inebilizumab reduced the risk of an NMOSD attack and has potential application as an evidence-based treatment for patients withNMOSD.